Olivia Cavlan is Alchemab’s Chief Corporate Development and Strategy Officer where she oversees global business development and partnerships and leads corporate strategy.
Prior to Alchemab Olivia was an Investment Principal at SV Health Investors and a Partner with McKinsey & Company where she was part of the leadership team in the Healthcare Private Equity and Pharmaceutical practices. While at McKinsey, Olivia co-led the global Real World Evidence practice and QuantumBlack biopharmaceutical offering where she led work on target discovery and clinical development. She has also led several global biopharma R&D transformation efforts and developed clinical and commercial strategies for a number of preclinical assets.
Olivia is a Non-Executive Director for the UK BioIndustry Association and a member of the Investment Committee for Cancer Research UK’s (CRUK) Seed fund. She also co-founded and sits on the Board of Directors of Sevenless Therapeutics, a small molecule pain company.
Olivia holds an MBChB in Medicine and a BSc in Pharmacology from Bristol University where she graduated with the top First Class Honors.